Opioids: From physical pain to the pain of social isolation

CNS Spectrums

Volumn 12, Issue 9, 2007, Pages 669-674

  Stein, Dan J ^a,b   Van Honk, Jack ^c   Ipser, Jonathan ^a   Solms, Mark ^a   Panksepp, Jaak ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

^d WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUPRENORPHINE; DIAMORPHINE; ENDORPHIN; ENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR AGONIST; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR;

ALCOHOLISM; ALLELE; ANALGESIA; ANXIETY DISORDER; ARTICLE; AUTISM; AUTOMUTILATION; CINGULATE GYRUS; CLINICAL ASSESSMENT; COGNITION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE PREDISPOSITION; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG RECEPTOR BINDING; EMOTIONAL ATTACHMENT; ENVIRONMENTAL FACTOR; GENETICS; HUMAN; IMPULSE CONTROL DISORDER; MAJOR DEPRESSION; MENTAL DISEASE; NERVE CONDUCTION; NEUROANATOMY; NEUROCHEMISTRY; NEUROSCIENCE; NEUROTRANSMISSION; OBSESSIVE COMPULSIVE DISORDER; PAIN; PATHOLOGICAL GAMBLING; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; PSYCHOTRAUMA; REWARD; SOCIAL ISOLATION; SUBSTANCE ABUSE;

EID: 35348862636     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900021490     Document Type: Article

References (64)

1. Bodnar RJ, Hadjimarkou MM. Endogenous opiates and behavior: 2001. Peptides. 2002;23:2307-2365.
2. Ribeiro SC, Kennedy SE, Smith YR, Stohler CS, Zubieta JK. Interface of physical and emotional stress regulation through the endogenous opioid system and [mu]-opioid receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1264-1280.
3. Cross AJ, Hille C, Slater P. Subtraction autoradiography of opiate receptor subtypes in human brain. Brain Res. 1987;418:343-348.
4. Frost JJ, Wagner HN, Dannals RF, et al. Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomog. 1985;9:231-236.
5. Lever JR. PET and SPECT imaging of the opioid system: receptors, radioligands and avenues for drug discovery and development. Curr Pharm Des. 2007;13:33-49.
6. Sugita S, North RA. Opioid actions on neurons of rat lateral amygdala in vitro. Brain Bes. 1993;612:151-155.
7. Wiedenmayer CP, Barr GA. Mu opioid receptors in the ventrolateral periaqueductal gray mediate stress-induced analgesia but not immobility in rat pups. Behav Neurosci. 2000;114:125-136.
8. Liberzon I, Zubieta JK, Fig LM, et al. mu-Opioid receptors and limbic responses to aversive emotional stimuli. Proc Natl Acad Sci U S A. 2002;99:7084-7089.
9. Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry. 1999;156:842-848.
10. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Euro J Pain. 2005;9:463-484.
11. Nelson EE, Panksepp J. Brain substrates of infant-mother attachment: contributions of opioids, oxytocin, and norepinephrine. Neurosci Biobehav Rev. 1998;22:437-452.
12. MacDonald AW, Cohen JD, Stenger VA, Carter CS. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science. 2000;288:1835-1838.
13. Sawamoto N, Honda M, Okada T, et al. Expectation of pain enhances responses to nonpainful somatosensory stimulation in the anterior cingulate cortex and parietal operculum/posterior insula: an event-related functional magnetic resonance imaging study. J Neurosci. 2000;20:7438-7445.
14. Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science. 1997;277:968-971.
15. Eisenberger NI, Lieberman MD, Williams KD. Does rejection hurt? An FMRI study of social exclusion. Science. 2003;302:290-292.
16. Panksepp J. Feeling the pain of social loss. Science. 2003;302:237-239.
17. Schlaepfer TE, Strain EC, Greenberg BD, et al. Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects. Am J Psychiatry. 1998;155:470-473.
18. Leppa M, Korvenoja A, Carlson S, et al. Acute opioid effects on human brain as revealed by functional magnetic resonance imaging. Neuroimage. 2006;31:661-669.
19. Becerra L, Harter K, Gonzalez RG, Borsook D. Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers. Anesth Analg. 2006;103:208-216.
20. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia - imaging a shared neuronal network. Science. 2002;295:1737-1740.
21. Shah YB, Haynes L, Prior MJ, Marsden CA, Morris PG, Chapman V. Functional magnetic resonance imaging studies of opioid receptor-mediated modulation of noxious-evoked BOLD contrast in rats. Psychopharmacology (Berl). 2005;180:761-773.
22. Wagner KJ, Sprenger T, Kochs EF, Tölle TR, Valet M, Willoch F. Imaging human cerebral pain modulation by dose-dependent opioid analgesia: a positron emission tomography activation study using remifentanil. Anesthesiology. 2007;106:548-556.
23. Zubieta JK, Smith YR, Bueller JA, et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science. 2001;293:311-315.
24. Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63:1199-1208.
25. Herman BH. A possible role of proopiomelanocortin peptides in self-injurious behavior. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:S109-S139.
26. Liberzon I, Taylor SF, Phan KL, et al. Altered central micro-opioid receptor binding after psychological trauma. Biol Psychiatry. 2007;61:1030-1038.
27. Ikeda K, Ide S, Han W, Hayashida M, Uhl GR, Sora I. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci. 2005;26:311-317.
28. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007;81:429-444.
29. Mayer P, Höllt V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics. 2006;16:1-7.
30. Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006;83:262-268.
31. Max MB, Wu T, Atlas SJ, Edwards RR, Haythornthwaite JA, Bollettino AF. A clinical genetic method to identify mechanisms by which pain causes depression and anxiety. Mol Pain. 2006;2:14.
32. Stein DJ, Newman TK, Savitz J, Ramesar R. Warriors vs worriers: the role of COMT gene variants. CNS Spectr. 2006;11:745-748.
33. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240-1243.
34. Panksepp, J. Why does separation distress hurt? Comment on MacDonald and Leary (2005). Psychol Bull. 2005;131:224-230.
35. Panksepp J, Panksepp JB. The seven sins of evolutionary psychology. Evolution and Cognition. 2000;6:108-131.
36. Macdonald G, Leary MR. Why does social exclusion hurt? The relationship between social and physical pain. Psychol Bull. 2005;131:202-223.
37. Panksepp J, Knutson B, Burgdorf J. The role of brain emotional systems in addictions: a neuro-evolutionary perspective and new 'self-report' animal model. Addiction. 2002;97:459-469.
38. Nesse RM, Berridge KC. Psychoactive drug use in evolutionary perspective. Science. 1997;278:63-66.
39. Gerald MS, Higley JD. Evolutionary underpinnings of excessive alcohol consumption. Addiction. 2002;97:415-425.
40. Kross E, Egner T, Ochsner K, Hirsch J, Downey G. Neural dynamics of rejection sensitivity. J Cogn Neurosci. 2007;19:945-956.
41. Downey G, Feldman SI. Implications of rejection sensitivity for intimate relationships. J Pers Soc Psychol. 1996;70:1327-1343.
42. Panksepp J. Affective Neuroscience: The Foundations of Human and Animal Emotions. New York, NY: Oxford University Press; 1998.
43. Schwartz AC, Bradley R, Penza KM, et al. Pain medication use among patients with posttraumatic stress disorder. Psychosomatics. 2006;47:136-142.
44. Zacny JP. Morphine responses in humans: a retrospective analysis of sex differences. Drug Alcohol Depend. 2001;63:23-28.
45. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2006;(2):CD002025.
46. Amato L, Davoli M, A Perucci C, Ferri M, Faggiano FP, Mattick R. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005;28:321-329.
47. Boothby LA, Doering PL. Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm. 2007;64:266-272.
48. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Bev. 2004;(4):CD005031.
49. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Bev. 2004;(4):CD004147.
50. Grant JE, Kim SW. Medication management of pathological gambling. Minn Med. 2006;89:44-48.
51. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2005;(1):CD001867.
52. Elchaar GM, Maisch NM, Auguste LM, Wehring HJ. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother 2006;40:1086-1095.
53. Symons FJ, Thompson A, Rodriquez MC. Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis. Ment Retard Dev Disabil Res Rev. 2004;10:193-200.
54. Kosten TR, Morgan C, Kosten TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 1990;7:51-54.
55. Gerra G, Leonardi C, D'Amore A. et al. Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:265-272.
56. Emrich HM, Vogt P, Herz A. Possible antidepressive effects of opioids: action of buprenorphine. Ann N Y Acad Sci. 1982;398:108-112.
57. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15:49-57.
58. Saxe G, Geary M, Bedard K, et al. Separation anxiety as a mediator between acute morphine administration and PTSD symptoms in injured children. Ann N Y Acad Sci. 2006;1071:41-45.
59. Bohus MJ, Landwehrmeyer GB, Stiglmayr CE. Limberger MR Böhme R, Schmahl CG. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry. 1999;60:598-603.
60. Glover H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr J Psychiatry Relat Sci. 1993;30:255-263.
61. Lubin G, Weizman A, Shmushkevitz M, Valevski A. Short-term treatment of posttraumatic stress disorder with naltrexone: an open-label preliminary study. Hum Psychopharmacol. 2002;17:181-185.
62. Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005;66:353-359.
63. Panksepp J. Brain opioids: a neurochemical substrate for narcotic and social dependence. In: Cooper SJ, ed. Progress in Theory in Psychopharmacology. London, England: Academic Press; 1981:149-175.
64. Panksepp J, Herman BH, Vilberg T, Bishop P, DeEskinazi FG. Endogenous opioids and social behavior. Neurosci Biobehav Revs. 1980;4:473-487.